Literature reports have demonstrated that reduced concentrations of decorin measured in ovarian cancer cells and tumour stroma correlated with histological malignancy, higher clinical stage (according to FIGO) and risk of metastasis [86]. This evidence concerns the gene DCN and ovarian cancer.